New combo therapy shows promise for tough prostate cancer
NCT ID NCT06909825
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the treatment can shrink tumors and lower PSA levels while monitoring side effects. Participants must have tried at least one prior hormone therapy and be in relatively good health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, 5037, Australia
-
Macquarie University Hospital
Macquarie Park, New South Wales, 2113, Australia
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
Conditions
Explore the condition pages connected to this study.